Support our online development, and advance our onground research initiatives in free market economics, as we seek to showcase the brightest Next-Gen minds.
THE ME-P DISCLAIMER: Posts, comments and opinions do not necessarily represent iMBA, Inc., but become our property after submission. Copyright © 2006 to-date. iMBA, Inc allows colleges, universities, medical and financial professionals and related clinics, hospitals and non-profit healthcare organizations to distribute our proprietary essays, photos, videos, audios and other documents; etc. However, please review copyright and usage information for each individual asset before submission to us, and/or placement on your publication or web site. Attestation references, citations and/or back-links are required. All other assets are property of the individual copyright holder.
Understanding DEA Perils
[By Dr. Charles F. Fenton III; Esq]
The Drug Enforcement Agency (DEA) controls the issuance of DEA numbers that permit the physician to prescribe controlled substances to their patients.
The use of controlled substances is important to almost all medical specialties.
Family practitioners use codeine to treat coughs and surgeons use narcotics to manage pain. The spectrum-of-use is wide.
The Dilemma
Unfortunately, there will always be a rogue physician willing to sell narcotic prescriptions. These physicians cause the DEA to cast a jaundiced eye towards all physicians.
However, the dilemma may be that there are simply too many stories of physicians who “over-use” controlled substances in a practice designed to ease the suffering of their patients; or not?
And, how do we differentiate among them all?
Assessment
The physician never knows when a patient coming into the office complaining of pain and asking for pain medication – whether that patient is truly in pain or not – is an undercover agent for the DEA.
Has it come to prescriber beware?
Conclusion
This peril and paranoia (combined with the risk of a malpractice claim of “hooking” the patient) causes some physicians to actually under prescribe pain medication. So, your thoughts on this ME-P are appreciated.
Speaker: If you need a moderator or speaker for an upcoming event, Dr. David E. Marcinko; MBA – Publisher-in-Chief of the Medical Executive-Post – is available for seminar or speaking engagements. Contact: MarcinkoAdvisors@msn.com
OUR OTHER PRINT BOOKS AND RELATED INFORMATION SOURCES:
- PRACTICES: www.BusinessofMedicalPractice.com
- HOSPITALS: http://www.crcpress.com/product/isbn/9781466558731
- CLINICS: http://www.crcpress.com/product/isbn/9781439879900
- ADVISORS: www.CertifiedMedicalPlanner.org
- FINANCE: Financial Planning for Physicians and Advisors
- INSURANCE: Risk Management and Insurance Strategies for Physicians and Advisors
- Dictionary of Health Economics and Finance
- Dictionary of Health Information Technology and Security
- Dictionary of Health Insurance and Managed Care
Share this:
Filed under: Drugs and Pharma |
The Leading Business Education Network for Doctors, Financial Advisors and Health Industry Consultants 
Real Time Drug Surveillance
Did you know that health insurance companies are finally beginning to mine their patient data to look for drug safety red flags?
It’s true! WellPoint Inc., in collaboration with the Food and Drug Administration [FDA], plans to launch one of the first real-time drug-surveillance systems. Starting early next year, the insurer will systematically scan the medical information of more than half of its 35 million members to look for hidden patterns or spikes in medical problems that might be linked to certain medication or combination of drugs; as reported in the Wall Street Journal [WSJ].
Until now, the drug-safety monitoring system used by the FDA has been spotty, slow and passive, relying largely on harried doctors and drug companies to report problems they see crop up with patients, and capturing less than 10 percent of bad reactions.
But, are there any other covert reasons for this economic altruism?
Like, MIB [Medical Information Bureau] reportage, for example.
Are there any comments on this life-saving, yet potentially inflammatory issue? Is there a potential for Protected Health Information [PHI] disclosure; despite HIPAA restrictions? Please opine?
-James
LikeLike